Shams’ili S, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126:1409–18.

Google Scholar 

Verschuuren J, et al. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. 1996;91:519–25.

CAS  Google Scholar 

Yshii L, Bost C, Liblau R. Immunological bases of paraneoplastic cerebellar degeneration and therapeutic implications. Front Immunol. 2020;11:991.

Tanaka M, Tanaka K, Onodera O, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg. 1995;97:95–100.

CAS  Google Scholar 

Tanaka K, et al. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg. 1995;97:101–5.

CAS  Google Scholar 

Saiki M, et al. Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization. J Autoimmun. 2005;24:203–8.

CAS  Google Scholar 

Sakai K, Shirakawa T, Kitagawa Y, Li Y, Hirose G. Induction of cytotoxic T lymphocytes specific for paraneoplastic cerebellar degeneration-associated antigen in vivo by DNA immunization. J Autoimmun. 2001;17:297–302.

CAS  Google Scholar 

Yshii LM, et al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain. 2016;139:2923–34.

Google Scholar 

Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852–63.

CAS  Google Scholar 

Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci. 1997;17:1406–15.

CAS  Google Scholar 

Eichler TW, et al. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS One. 2013;8(6):e66002.

Kråkenes T, et al. CDR2L is the major Yo antibody target in paraneoplastic cerebellar degeneration. Ann Neurol. 2019;86:316–21.

Google Scholar 

Gebauer C, et al. CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model. OncoImmunology. 2017;6:e1260212.

Google Scholar 

Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies. OncoImmunology. 2013;2:e27384.

Google Scholar 

Albert ML, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. 1998;4:1321–4.

CAS  Google Scholar 

Small M, et al. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. 2018;135:569–79.

CAS  Google Scholar 

Roby KF, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–91.

CAS  Google Scholar 

Flies DB, Chen L. A simple and rapid vortex method for preparing antigen/adjuvant emulsions for immunization. J Immunol Methods. 2003;276:239–42.

CAS  Google Scholar 

Liu L, and Duff K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. JoVE. 2008;960. https://doi.org/10.3791/960

Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005;28:220–8.

CAS  Google Scholar 

Longhi MP, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009;206:1589–602.

CAS  Google Scholar 

Mookerjee A, Graciotti M, Kandalaft LE. A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model. Bioimpacts. 2018;8:211–21.

CAS  Google Scholar 

Shibaki A, Katz SI. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund’s adjuvant. Exp Dermatol. 2002;11:126–34.

CAS  Google Scholar 

Bennett SRM, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478.

CAS  Google Scholar 

Llopiz D, et al. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immunother. 2008;57:19–29.

CAS  Google Scholar 

Hofstetter HH, Shive CL, Forsthuber TG. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund’s adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol. 2002;169:117–25.

CAS  Google Scholar 

Fujimoto C, et al. Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J Immunol. 2006;177:6896–903.

CAS  Google Scholar 

Cassan C, et al. Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. J Immunol. 2006;177:1552–60.

CAS  Google Scholar 

Millward JM, Caruso M, Campbell IL, Gauldie J, Owens T. IFN-γ-induced chemokines synergize with pertussis toxin to promote T cell entry to the central nervous system. J Immunol. 2007;178:8175–82.

CAS  Google Scholar 

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591–603.

CAS  Google Scholar 

Woo S-R, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–27.

CAS  Google Scholar 

Joncker NT, Bettini S, Boulet D, Guiraud M, Guerder S. The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes. Eur J Immunol. 2016;46:609–18.

CAS  Google Scholar 

Chiang CL-L, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol. 2010;22:132–43.

CAS  Google Scholar 

Scheffer SR, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer. 2003;103:205–11.

CAS  Google Scholar 

Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76:1683–9.

CAS  Google Scholar 

McCaw TR, Randall TD, Arend RC. Overcoming immune suppression with epigenetic modification in ovarian cancer. Transl Res. 2019;204:31–8.

CAS  Google Scholar 

Stone ML, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A. 2017;114:E10981–90.

CAS  Google Scholar 

Turner TB, et al. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget. 2017;8:44159–70.

Google Scholar 

Giometto B, et al. Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol. 1997;23:468–74.

CAS  Google Scholar 

Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand. 2009;120:64–7.

CAS  Google Scholar 

Su SB, Silver PB, Zhang M, Chan C-C, Caspi RR. Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals. J Immunol. 2001;167:250–6.

CAS  Google Scholar 

Schläger C, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature. 2016;530:349–53.

Google Scholar 

Maria Z, Turner E, Agasing A, Kumar G, Axtell RC. Pertussis toxin inhibits encephalitogenic T-cell infiltration and promotes a B-cell-driven disease during Th17-EAE. Int J Mol Sci. 2021;22:2924.

CAS  Google Scholar 

Tanaka K, et al. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci. 1994;127:153–8.

CAS  Google Scholar 

Tanaka M, Tanaka K, Shinozawa K, Idezuka J, Tsuji S. Cytotoxic T cells react with recombinant Yo protein from a patient with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci. 1998;161:88–90.

CAS  Google Scholar 

Carpentier AF, et al. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res. 1998;4:2819–24.

CAS  Google Scholar 

Pellkofer H, et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain. 2004;127:1822–30.

Google Scholar 

Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol. 2014;128:835–52.

CAS  Google Scholar 

Panja D, Vedeler CA, Schubert M. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. Neuropathol Appl Neurobiol. 2019;45:141–56.

CAS  Google Scholar 

Greenlee JE, Burns JB, Rose JW, Jaeckle KA, Clawson S. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. Acta Neuropathol. 1995;89:341–5.

CAS  Google Scholar 

Graus F, et al. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci. 1991;106:82–7.

CAS  Google Scholar 

Sellers RS. Translating mouse models: immune variation and efficacy testing. Toxicol Pathol. 2017;45:134–45.

CAS  Google Scholar 

Blachère NE, et al. T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur J Immunol. 2014;44:3240–51.

Google Scholar 

Tsou P, Katayama H, Ostrin EJ, Hanash SM. The emerging role of B cells in tumor immunity. Cancer Res. 2016;76:5597–601.

CAS  Google Scholar 

Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol. 2015;15:441–51.

CAS  Google Scholar 

Small M, et al. Specific genetic alterations and tumor immune contexture characterize ovarian tumors with paraneoplastic degeneration and anti-Yo antibodies. Morphologie. 2017;101:245.

Google Scholar 

Peter E, et al. Immune and genetic signatures of breast carcinomas triggering anti-Yo–associated paraneoplastic cerebellar degeneration. Neurol-Neuroimmunol Neuroinflammation. 2022;9(5):e20001.

Lv D, et al. The similar expression pattern of MHC class I molecules in human and mouse cerebellar cortex. Neurochem Res. 2014;39:180–6.

CAS  Google Scholar 

Yshii L, et al. IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration. JCI Insight. 2019;4(7):e127001.

Cebrián C, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014;5:3633.

Google Scholar